Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Launched by PROKIDNEY · Oct 18, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating a treatment called REACT for people with Type 2 Diabetes Mellitus (T2DM) who also have chronic kidney disease (CKD). The main goal is to see if two injections of REACT, given three months apart, are safe and effective for improving kidney health. Participants will receive these injections in both kidneys, either from a biopsy or without one. The study is currently looking for participants aged 30 to 80 who have a diagnosis of T2DM and diabetic kidney disease, and who meet certain health criteria, such as having stable blood sugar levels and specific kidney function measurements.

If someone is eligible and decides to join the trial, they can expect to receive regular health checks and monitoring while receiving the injections. This study is important because it aims to find out if REACT can help manage kidney problems in people with diabetes, potentially improving their overall health. However, certain individuals, such as those with other kidney diseases or serious heart conditions, may not be able to participate, as these factors could affect the study's results.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The participant is male or female, 30 to 80 years of age on the date of informed consent.
• • 2. The participant has a clinical diagnosis of T2DM in their health record.
• • 3. The participant has a clinical diagnosis of diabetic nephropathy as the underlying cause of renal disease (diagnosis does not have to be confirmed via renal biopsy) in their health record.
• • 4. The participant has a serum glycosylated hemoglobin (HbA1c) less than 9.5% at the Screening Visit.
• 5. The participant has a documented clinical diagnosis of either:
• • eGFR greater than or equal to 20 and less than 30 mL/min/1.73m², not requiring renal dialysis. UACR level cannot exceed 5000 mg/g (565 mg/mmol) OR: eGFR of 30 to less than or equal to 35 mL/min/1.73m² AND UACR of 300 to less than or equal to 5000mg/g (33.9 mg/mmol to less than or equal to 565 mg/mmol).
• • 6. Systolic blood pressure of ≤ 140 mm Hg and diastolic blood pressure of ≤ 90 mm Hg at Screening (based on the average of 3 measurements obtained while seated) and maintained during the screening period until randomization.
• • 7. On a clinically relevant and stable dose of an angiotensin converting-enzyme inhibitor (ACEI) OR an angiotensin receptor blocker (ARB), unless not tolerated or contraindicated.
• Exclusion Criteria:
• • 1. The participant has a history of type 1 diabetes mellitus.
• • 2. The participant has a history of renal transplantation or other organ transplantation (corneal transplants are not an exclusion), solitary kidney, recurrent complicated urinary tract infections or complicated kidney stones. Urinary tract infections identified prior to renal biopsy or injection should be resolved prior to procedures.
• • 3. The participant has any other known underlying cause of kidney disease, including but not limited to: Autosomal dominant and recessive polycystic kidney disease, primary focal segmental glomerulosclerosis, vasculitis related CKD, IgA nephropathy and other immune modulated nephropathies, drug-induced CKD or other types of CKD or anatomic variants as determined by the Investigator or Sponsor that would interfere with biopsy and REACT injection procedure or confound study assessments.
• • 4. History of acute kidney injury within 3 months prior to the Screening Visit.
• • 5. Myocardial infarction, unstable angina, revascularization procedure (e.g. stent or bypass graft surgery), or cerebrovascular accident within 12 weeks before randomization, or a revascularization procedure is planned during the trial.